Form 4: Cryo-Cell CFO Granted 30,000 Performance Stock Options

Cryo-Cell International's VP Finance and CFO, Jill M. Taymans, was granted 30,000 stock options with performance-based vesting conditions.

Summary

• Jill M. Taymans, VP Finance and CFO of Cryo-Cell International Inc. (CCEL), acquired 30,000 derivative securities (stock options) on January 7, 2026.
• These options have an exercise price of $3.54 per share and are set to expire on January 7, 2031.
• One tranche of 10,000 options vests 1/3 upon issuance, 1/3 on January 7, 2027, and 1/3 on January 7, 2028.
• Another tranche of 20,000 options, granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan, vests in three equal tranches subject to both time-based vesting (after the 1st, 2nd, and 3rd anniversaries of the grant date) and stock-price performance conditions.
• The performance conditions for the 20,000 options require the company's common stock to achieve an average closing price of at least $6, $8, and $10 per share, respectively, over 20 consecutive trading days for each tranche to vest.
• Following these transactions, Ms. Taymans beneficially owns 45,396 shares of common stock directly and 84,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of performance-based stock options to a key executive is generally a positive signal, aligning management incentives with shareholder value. The specific stock price targets ($6, $8, $10) suggest internal confidence in future growth. However, it's a routine compensation event rather than a major strategic announcement, hence a moderate positive score.

Positives

• The grant of stock options, particularly those with performance-based vesting conditions tied to stock price appreciation ($6, $8, and $10 targets), aligns management's interests with shareholder value creation.
• Increased insider ownership through option grants can signal confidence in the company's future prospects and commitment to long-term growth.

Future Outlook

The performance-based vesting conditions for a portion of the newly granted stock options, tied to the company's common stock achieving average closing prices of $6, $8, and $10 per share over 20 consecutive trading days, indicate management's internal targets or expectations for future stock price appreciation.

Industry Context

The granting of stock options to key executives is a standard practice in many industries, including biotechnology and healthcare, to incentivize performance and align executive interests with long-term shareholder value. The specific performance hurdles tied to stock price appreciation reflect a common strategy to motivate executives to achieve market-recognized growth.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact as executive compensation is tied to stock performance, aligning interests. The performance hurdles could indicate management's belief in future stock price appreciation.

Next Steps

• Continued service of the reporting person to the company for vesting conditions to be met.
• Monitoring of Cryo-Cell International's stock price to meet the performance-based vesting conditions for the 20,000 options.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the grant of stock options. While the performance-based vesting conditions are a positive signal for aligning management incentives with shareholder value, this filing alone does not provide sufficient new information to warrant a change in investment recommendation. It confirms ongoing executive commitment and a compensation structure designed to reward stock price appreciation, but does not present new fundamental data or strategic shifts that would alter a 'hold' stance based on broader company fundamentals.

Keywords

Cryo-Cell International, CCEL, Jill M. Taymans, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Performance Vesting, Cryo-Cell 2022 Stock Incentive Plan